MetaCap

Cullinan Therapeutics Inc. (CGEM)

NASDAQ: CGEMHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

8.89-0.18 (-1.98%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CGEM stock chart

Technical analysis

Key statistics

All statistics
Market cap
$577.15M
EPS (TTM)
-$3.09
52-week range
8.47 – 23.19
Day range
8.80 – 9.43
Volume / Avg
1.01M / 997.14K
Beta
—

52-week range

$8.47$23.19

CGEM stock today

Cullinan Therapeutics (CGEM) closed at $8.89 on Nov 20, down 1.98% (-$0.18), versus the S&P 500's 3.70% decline. At this level, CGEM sits near the bottom of its 52-week range of $8.47 to $23.19: 61.7% below the high, set on Aug 26, 2026 and 5.0% above the low. CGEM is down 14.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 6.1%.

Cullinan Therapeutics has posted a net loss over the last twelve months (EPS of -$3.09), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Cullinan Therapeutics

Company profile

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Nadim Ahmed M.S.
Headquarters
Cambridge, MA
Employees
109
IPO year
2021

Financial highlights

Full financials

Cullinan Therapeutics reported a net loss of $219.9 million, compared with a loss of $167.4 million a year earlier.

Cullinan Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue———$0$18.94M
Growth———-100.00%—
Net income$-219.88M$-167.38M$-153.16M$111.21M$-65.57M
EPS (diluted)——$-3.69$2.38$-1.52

Analyst forecast

Forecast

Consensus (12 analysts)

strong_buy

Avg. price target

$34.27+285.49%

  • Strong buy 1
  • Buy 11
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $27.00High $44.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$-0.74 vs $-0.79
Surprise
+6.33%

CGEM news

All CGEM news

Cullinan Therapeutics peers

Health Care sector
CGEM peer companies
CompanyPrice% ChgMarket capCompare
SRZNSurrozen Inc.28.46-7.21%$596.40Mvs CGEM
FDMT4D Molecular Therapeutics Inc.10.23-4.57%$576.76Mvs CGEM
ENTXEntera Bio Ltd.3.31+0.76%$575.53Mvs CGEM
DBVTDBV Technologies S.A. ADR9.02-4.25%$566.82Mvs CGEM
IAMIambic Therapeutics Inc.13.11-8.06%$621.42Mvs CGEM
ETRAElectra Therapeutics Inc.8.11-9.28%$509.85Mvs CGEM
VALNValneva SE ADR5.16-3.82%$490.86Mvs CGEM
ATTOAttovia Therapeutics Inc.15.10-3.08%$690.26Mvs CGEM

Indexes, lists and sector

Cullinan Therapeutics stock FAQ

What is Cullinan Therapeutics's stock price today?

CGEM last traded at $8.89 as of Nov 20, 4:00 PM EST, down 1.98% on the day. Prices are delayed at least 15 minutes.

Who is Cullinan Therapeutics's CEO?

Mr. Nadim Ahmed M.S. is the chief executive officer of Cullinan Therapeutics Inc., which has about 109 employees.

What is the CGEM 52-week high?

The 52-week high for CGEM is $23.19 and the 52-week low is $8.47. The stock is currently 61.7% below its high.

Compare CGEM